{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:49:07Z","timestamp":1791676147727,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12877-6","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:36:14Z","timestamp":1791668174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA methylation-mediated regulation of TRAIL pathway components (DR5, DcR2, and CASP3) in breast cancer: molecular mechanisms and therapeutic implications"],"prefix":"10.1007","volume":"53","author":[{"given":"Nuzhat","family":"Khursheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Qurat-ul-Quadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allah-u-deen","family":"Khursheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Asiaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Showkat Ahmad","family":"Ganie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"12877_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036905","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU (2024) Breast cancer: a review of risk factors and diagnosis. Medicine (Baltimore) 103:e36905","journal-title":"Medicine (Baltimore)"},{"key":"12877_CR2","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.s432526","author":"J Wang","year":"2023","unstructured":"Wang J, Wu S-G (2023) Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer Targets Ther. https:\/\/doi.org\/10.2147\/bctt.s432526","journal-title":"Breast Cancer Targets Ther"},{"key":"12877_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40291-018-0329-9","volume":"22","author":"AP Mishra","year":"2018","unstructured":"Mishra AP, Salehi B, Sharifi-Rad M et al (2018) Programmed cell death, from a cancer perspective: an overview. Mol Diagn Ther 22:281\u2013295","journal-title":"Mol Diagn Ther"},{"key":"12877_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512222","volume":"24","author":"N Bou Antoun","year":"2023","unstructured":"Bou Antoun N, Chioni A-M (2023) Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci 24:12222","journal-title":"Int J Mol Sci"},{"key":"12877_CR5","doi-asserted-by":"crossref","unstructured":"Jan R (2019) Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharma Bull 9: 205","DOI":"10.15171\/apb.2019.024"},{"key":"12877_CR6","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1210\/jc.2002-021905","volume":"88","author":"M Lonergan","year":"2003","unstructured":"Lonergan M, Aponso D, Marvin K et al (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab 88:3835\u20133844","journal-title":"J Clin Endocrinol Metab"},{"key":"12877_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","volume":"30","author":"A Montinaro","year":"2023","unstructured":"Montinaro A, Walczak H (2023) Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ 30:237\u2013249","journal-title":"Cell Death Differ"},{"key":"12877_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","volume":"12","author":"L Zhang","year":"2005","unstructured":"Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228\u2013237","journal-title":"Cancer Gene Ther"},{"key":"12877_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/epi.13.43","volume":"5","author":"M Ehrlich","year":"2013","unstructured":"Ehrlich M, Lacey M (2013) DNA methylation and differentiation: silencing, upregulation and modulation of gene expression. Epigenomics 5:553\u2013568","journal-title":"Epigenomics"},{"key":"12877_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2021.5278","volume":"59","author":"MT Vietri","year":"2021","unstructured":"Vietri MT, D\u2019elia G, Benincasa G et al (2021) DNA methylation and breast cancer: a way forward. Int J Oncol 59:1\u201312","journal-title":"Int J Oncol"},{"key":"12877_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B (2023) Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther 8:69","journal-title":"Signal Transduct Target Ther"},{"key":"12877_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal R, Gupta S (2012) Epigenetic modifications in cancer. Clin Genet 81:303\u2013311","journal-title":"Clin Genet"},{"key":"12877_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174363","volume":"13","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Trougakos IP, Erin N, Papageorgis P (2021) Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers Basel 13:4363","journal-title":"Cancers Basel"},{"key":"12877_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(00)00193-5","volume":"2","author":"I Tamm","year":"2001","unstructured":"Tamm I, Schriever F, D\u00f6rken B (2001) Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2:33\u201342","journal-title":"Lancet Oncol"},{"key":"12877_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/1120009X.2023.2278014","volume":"36","author":"H Dou","year":"2024","unstructured":"Dou H, Yu PY, Liu YQ et al (2024) Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review. J Chemother 36:370\u2013388","journal-title":"J Chemother"},{"key":"12877_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","volume":"39","author":"C Falschlehner","year":"2007","unstructured":"Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39:1462\u20131475","journal-title":"Int J Biochem Cell Biol"},{"key":"12877_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1549808","volume":"16","author":"X Qiao","year":"2025","unstructured":"Qiao X, Guo S, Meng Z et al (2025) Advances in the study of death receptor 5. Front Pharmacol 16:1549808","journal-title":"Front Pharmacol"},{"key":"12877_CR18","unstructured":"O\u2019Leary L (2012) Decoy Receptors block tumour cell eradication by TRAIL-Molecular engineering of TRAIL to evade decoy receptors."},{"key":"12877_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/jmg.2009.066944","volume":"46","author":"S Ghavami","year":"2009","unstructured":"Ghavami S, Hashemi M, Ande SR et al (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46:497\u2013510","journal-title":"J Med Genet"},{"key":"12877_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699746","volume":"12","author":"E Razeghian","year":"2021","unstructured":"Razeghian E, Suksatan W, Rahman HS et al (2021) Harnessing TRAIL-induced apoptosis pathway for cancer immunotherapy and associated challenges. Front Immunol 12:699746","journal-title":"Front Immunol"},{"key":"12877_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.ctdb.2015.07.012","volume":"114","author":"AL Anding","year":"2015","unstructured":"Anding AL, Baehrecke EH (2015) Autophagy in cell life and cell death. Curr Top Dev Biol 114:67\u201391","journal-title":"Curr Top Dev Biol"},{"key":"12877_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.0.0070257","volume":"7","author":"R Kumar","year":"2000","unstructured":"Kumar R, Vadlamudi R, Adam L (2000) Apoptosis in mammary gland and cancer. Endocr Relat Cancer 7:257\u2013269","journal-title":"Endocr Relat Cancer"},{"key":"12877_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.9734\/bji\/2025\/v29i2769","volume":"29","author":"S Zameer","year":"2025","unstructured":"Zameer S, Akram Z, Daniyal A et al (2025) Apoptosis mechanisms: role of anti-apoptotic proteins, cancer hallmarks and tumor microenvironment in cancer cell survival. Biotechnol J Int 29:27\u201336","journal-title":"Biotechnol J Int"},{"key":"12877_CR24","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1089\/ars.2009.2692","volume":"11","author":"M Landriscina","year":"2009","unstructured":"Landriscina M, Maddalena F, Laudiero G, Esposito F (2009) Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 11:2701\u20132716","journal-title":"Antioxid Redox Signal"},{"key":"12877_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.bjp.0704549","volume":"135","author":"DJ MacEwan","year":"2002","unstructured":"MacEwan DJ (2002) TNF ligands and receptors\u2013a matter of life and death. Br J Pharmacol 135:855","journal-title":"Br J Pharmacol"},{"key":"12877_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11912-022-01199-y","volume":"24","author":"P Singh","year":"2022","unstructured":"Singh P, Lim B (2022) Targeting apoptosis in cancer. Curr Oncol Rep 24:273\u2013284","journal-title":"Curr Oncol Rep"},{"key":"12877_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10495-022-01774-5","volume":"27","author":"KXJ Jong","year":"2022","unstructured":"Jong KXJ, Mohamed EHM, Ibrahim ZA (2022) Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer. Apoptosis 27:787\u2013799","journal-title":"Apoptosis"},{"key":"12877_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.bcp.2010.03.011","volume":"80","author":"M Russo","year":"2010","unstructured":"Russo M, Mupo A, Spagnuolo C, Russo GL (2010) Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol 80:674\u2013682","journal-title":"Biochem Pharmacol"},{"key":"12877_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/JLB.3MR0420-305R","volume":"109","author":"P Orning","year":"2021","unstructured":"Orning P, Lien E (2021) Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. J Leukoc Biol 109:121\u2013141","journal-title":"J Leukoc Biol"},{"key":"12877_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/carcin\/bgh283","volume":"26","author":"R Gerl","year":"2005","unstructured":"Gerl R, Vaux DL (2005) Apoptosis in the development and treatment of cancer. Carcinogenesis 26:263\u2013270","journal-title":"Carcinogenesis"},{"key":"12877_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41556-024-01429-4","volume":"26","author":"HL Glover","year":"2024","unstructured":"Glover HL, Schreiner A, Dewson G, Tait SW (2024) Mitochondria and cell death. Nat Cell Biol 26:1434\u20131446","journal-title":"Nat Cell Biol"},{"key":"12877_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.32604\/biocell.2021.013993","volume":"45","author":"S Dandoti","year":"2021","unstructured":"Dandoti S (2021) Mechanisms adopted by cancer cells to escape apoptosis\u2013a review. Biocell 45:863","journal-title":"Biocell"},{"key":"12877_CR33","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/sj.leu.2403497","volume":"18","author":"O Micheau","year":"2004","unstructured":"Micheau O, M\u00e9rino D (2004) Controlling TRAIL-mediated caspase-3 activation. Leukemia 18:1578\u20131580","journal-title":"Leukemia"},{"key":"12877_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/hdy.2010.54","volume":"105","author":"E Gibney","year":"2010","unstructured":"Gibney E, Nolan C (2010) Epigenetics and gene expression. Heredity 105:4\u201313","journal-title":"Heredity"},{"key":"12877_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.molonc.2010.04.002","volume":"4","author":"J Jovanovic","year":"2010","unstructured":"Jovanovic J, R\u00f8nneberg JA, Tost J, Kristensen V (2010) The epigenetics of breast cancer. Mol Oncol 4:242\u2013254","journal-title":"Mol Oncol"},{"key":"12877_CR36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","volume":"55","author":"X Xu","year":"2023","unstructured":"Xu X, Peng Q, Jiang X et al (2023) Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp Mol Med 55:1357\u20131370","journal-title":"Exp Mol Med"},{"key":"12877_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13072-017-0130-8","volume":"10","author":"JR Edwards","year":"2017","unstructured":"Edwards JR, Yarychkivska O, Boulard M, Bestor TH (2017) DNA methylation and DNA methyltransferases. Epigenetics Chromatin 10:23","journal-title":"Epigenetics Chromatin"},{"key":"12877_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13072-021-00400-z","volume":"14","author":"XG Pappalardo","year":"2021","unstructured":"Pappalardo XG, Barra V (2021) Losing DNA methylation at repetitive elements and breaking bad. Epigenetics Chromatin 14:25","journal-title":"Epigenetics Chromatin"},{"key":"12877_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13148-015-0157-2","volume":"7","author":"C Nervi","year":"2015","unstructured":"Nervi C, De Marinis E, Codacci-Pisanelli G (2015) Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics 7:127","journal-title":"Clin Epigenetics"},{"key":"12877_CR40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/cells2030545","volume":"2","author":"E Hervouet","year":"2013","unstructured":"Hervouet E, Cheray M, Vallette FM, Cartron P-F (2013) DNA methylation and apoptosis resistance in cancer cells. Cells 2:545\u2013573","journal-title":"Cells"},{"key":"12877_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/11782234251355663","volume":"19","author":"Q Maqsood","year":"2025","unstructured":"Maqsood Q, Khan MU, Fatima T, Khalid S, Malik ZI (2025) Recent insights into breast cancer: molecular pathways, epigenetic regulation, and emerging targeted therapies. Breast Cancer Basic Clin Res 19:11782234251355663","journal-title":"Breast Cancer Basic Clin Res"},{"key":"12877_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-017-4488-x","volume":"167","author":"DN Danforth","year":"2018","unstructured":"Danforth DN (2018) Molecular profile of atypical hyperplasia of the breast. Breast Cancer Res Treat 167:9\u201329","journal-title":"Breast Cancer Res Treat"},{"key":"12877_CR43","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.3390\/ijms12074465","volume":"12","author":"F-F Cai","year":"2011","unstructured":"Cai F-F, Kohler C, Zhang B, Wang M-H, Chen W-J, Zhong X-Y (2011) Epigenetic therapy for breast cancer. Int J Mol Sci 12:4465\u20134487","journal-title":"Int J Mol Sci"},{"key":"12877_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ijc.20041","volume":"109","author":"N Shivapurkar","year":"2004","unstructured":"Shivapurkar N, Toyooka S, Toyooka KO et al (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109:786\u2013792","journal-title":"Int J Cancer"},{"key":"12877_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2019.07.002","volume":"40","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zheng S, Luo Q, Huang X, Li Z (2019) Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma. Am J Otolaryngol 40:102258","journal-title":"Am J Otolaryngol"},{"key":"12877_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060850","volume":"11","author":"MI Elmallah","year":"2019","unstructured":"Elmallah MI, Micheau O (2019) Epigenetic regulation of TRAIL signaling: implication for cancer therapy. Cancers (Basel) 11:850","journal-title":"Cancers (Basel)"},{"key":"12877_CR47","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/genes12060864","volume":"12","author":"A Watanabe","year":"2021","unstructured":"Watanabe A, Miyake K, Akahane K et al (2021) Epigenetic modification of death receptor genes for TRAIL and TRAIL resistance in childhood B-cell precursor acute lymphoblastic leukemia. Genes (Basel) 12:864","journal-title":"Genes (Basel)"},{"key":"12877_CR48","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbrc.2013.10.114","volume":"441","author":"M Venza","year":"2013","unstructured":"Venza M, Visalli M, Catalano T et al (2013) Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun 441:743\u2013750","journal-title":"Biochem Biophys Res Commun"},{"key":"12877_CR49","doi-asserted-by":"publisher","DOI":"10.15407\/ubj88.05.018","author":"O Minchenko","year":"2016","unstructured":"Minchenko O, Tsymbal D, Minchenko D, Ratushna O (2016) The role of the TNF receptors and apoptosis inducing ligands in tumor growth. Ukr Biochem J. https:\/\/doi.org\/10.15407\/ubj88.05.018","journal-title":"Ukr Biochem J"},{"key":"12877_CR50","unstructured":"Jones DT (2002) The role of death receptor ligation and signal trandsuction inhibition in the killing of leukaemia cells by cytotoxic drugs and radiation, University of London, University College London (United Kingdom),"},{"key":"12877_CR51","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1158\/0008-5472.CAN-10-4026","volume":"71","author":"VK Hill","year":"2011","unstructured":"Hill VK, Ricketts C, Bieche I et al (2011) Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 71:2988\u20132999","journal-title":"Cancer Res"},{"key":"12877_CR52","doi-asserted-by":"publisher","first-page":"9169","DOI":"10.1158\/0008-5472.CAN-05-0939","volume":"65","author":"X Liu","year":"2005","unstructured":"Liu X, Yue P, Khuri FR, Sun S-Y (2005) Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 65:9169\u20139175","journal-title":"Cancer Res"},{"key":"12877_CR53","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","volume":"445","author":"W Xue","year":"2007","unstructured":"Xue W, Zender L, Miething C et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656\u2013660","journal-title":"Nature"},{"key":"12877_CR54","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/bab.2233","volume":"69","author":"M Asadi","year":"2022","unstructured":"Asadi M, Taghizadeh S, Kaviani E et al (2022) Caspase-3: structure, function, and biotechnological aspects. Biotechnol Appl Biochem 69:1633\u20131645","journal-title":"Biotechnol Appl Biochem"},{"key":"12877_CR55","first-page":"165","volume":"34","author":"M Fiandalo","year":"2012","unstructured":"Fiandalo M, Kyprianou N (2012) Caspase control: protagonists of cancer cell apoptosis. Exp Oncol 34:165","journal-title":"Exp Oncol"},{"key":"12877_CR56","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202201159","volume":"221","author":"E Eskandari","year":"2022","unstructured":"Eskandari E, Eaves CJ (2022) Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol 221:e202201159","journal-title":"J Cell Biol"},{"key":"12877_CR57","unstructured":"Ponnusamy L (2017) Epigenetic mechanism of acquired doxorubcin resistance in breast cancer cells."},{"key":"12877_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02213-2","volume":"21","author":"R Elango","year":"2021","unstructured":"Elango R, Vishnubalaji R, Shaath H, Alajez NM (2021) Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition. Cancer Cell Int 21:515","journal-title":"Cancer Cell Int"},{"key":"12877_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1839-z","volume":"15","author":"G Rodr\u00edguez-Berriguete","year":"2015","unstructured":"Rodr\u00edguez-Berriguete G, Torrealba N, Ortega MA et al (2015) Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy. BMC Cancer 15:809","journal-title":"BMC Cancer"},{"key":"12877_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43556-023-00126-2","volume":"4","author":"Z Xie","year":"2023","unstructured":"Xie Z, Zhou Z, Yang S, Zhang S, Shao B (2023) Epigenetic regulation and therapeutic targets in the tumor microenvironment. Mol Biomed 4:17","journal-title":"Mol Biomed"},{"key":"12877_CR61","doi-asserted-by":"publisher","first-page":"8918","DOI":"10.1158\/0008-5472.CAN-09-2608","volume":"69","author":"J Frasor","year":"2009","unstructured":"Frasor J, Weaver A, Pradhan M et al (2009) Positive cross-talk between estrogen receptor and NF-\u03baB in breast cancer. Cancer Res 69:8918\u20138925","journal-title":"Cancer Res"},{"key":"12877_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X (2024) A comprehensive review of HER2 in cancer biology and therapeutics. Genes 15:903","journal-title":"Genes"},{"key":"12877_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S-c (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61","journal-title":"Breast Cancer Res"},{"key":"12877_CR64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","volume":"19","author":"DW Stuckey","year":"2013","unstructured":"Stuckey DW, Shah K (2013) TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 19:685\u2013694","journal-title":"Trends Mol Med"},{"key":"12877_CR65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","volume":"37","author":"X Yuan","year":"2018","unstructured":"Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS (2018) Developing TRAIL\/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev 37:733\u2013748","journal-title":"Cancer Metastasis Rev"},{"key":"12877_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib6040016","volume":"6","author":"A Dubuisson","year":"2017","unstructured":"Dubuisson A, Micheau O (2017) Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies 6:16","journal-title":"Antibodies"},{"key":"12877_CR67","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1158\/1078-0432.CCR-14-2780","volume":"21","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Varley KE, Abramson VG et al (2015) TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer. Clin Cancer Res 21:2722\u20132729","journal-title":"Clin Cancer Res"},{"key":"12877_CR68","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1158\/1078-0432.CCR-14-2780","volume":"21","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Varley KE, Abramson VG et al (2015) TBCRC 019: an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC or Abraxane\u00ae) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer. Clin Cancer Res 21:2722","journal-title":"Clin Cancer Res"},{"key":"12877_CR69","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1517\/14728222.2010.519701","volume":"14","author":"J Abdulghani","year":"2010","unstructured":"Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14:1091\u20131108","journal-title":"Expert Opin Ther Targets"},{"key":"12877_CR70","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1158\/1541-7786.MCR-04-0136","volume":"3","author":"P Horak","year":"2005","unstructured":"Horak P, Pils D, Haller G et al (2005) Contribution of epigenetic silencing of tumor necrosis factor\u2013related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3:335\u2013343","journal-title":"Mol Cancer Res"},{"key":"12877_CR71","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1158\/1535-7163.MCT-06-0521","volume":"6","author":"S Baritaki","year":"2007","unstructured":"Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B (2007) Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 6:1387\u20131399","journal-title":"Mol Cancer Ther"},{"key":"12877_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10142-025-01552-x","volume":"25","author":"A Zahoor","year":"2025","unstructured":"Zahoor A, Khazer R, Mehraj I et al (2025) Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases. Funct Integr Genomics 25:50","journal-title":"Funct Integr Genomics"},{"key":"12877_CR73","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1038\/sj.onc.1206044","volume":"21","author":"E Devarajan","year":"2002","unstructured":"Devarajan E, Sahin AA, Chen JS et al (2002) Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21:8843\u20138851","journal-title":"Oncogene"},{"key":"12877_CR74","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2174\/1570159X16666180302115544","volume":"16","author":"E Sekerdag","year":"2018","unstructured":"Sekerdag E, Solaroglu I, Gursoy-Ozdemir Y (2018) Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr Neuropharmacol 16:1396\u20131415","journal-title":"Curr Neuropharmacol"},{"key":"12877_CR75","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/17501911.2026.2637418","volume":"18","author":"DC Michael","year":"2026","unstructured":"Michael DC, Mehdipour P (2026) DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions. Epigenomics 18:463\u2013491","journal-title":"Epigenomics"},{"key":"12877_CR76","first-page":"2989","volume":"33","author":"A Gnyszka","year":"2013","unstructured":"Gnyszka A, Jastrz\u0119bski Z, Flis S (2013) DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 33:2989\u20132996","journal-title":"Anticancer Res"},{"key":"12877_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182953","volume":"17","author":"FR Riyas Mohamed","year":"2025","unstructured":"Riyas Mohamed FR, Aldubaisi S, Akbar A, Khan MI, Yaqinuddin A (2025) Epigenetic reprogramming by decitabine in triple-negative breast cancer: mechanisms, immune modulation, and therapeutic synergy. Cancers (Basel) 17:2953","journal-title":"Cancers (Basel)"},{"key":"12877_CR78","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","volume":"20","author":"M Berdasco","year":"2019","unstructured":"Berdasco M, Esteller M (2019) Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet 20:109\u2013127","journal-title":"Nat Rev Genet"},{"key":"12877_CR79","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/1476-4598-9-305","volume":"9","author":"GL Gravina","year":"2010","unstructured":"Gravina GL, Festuccia C, Marampon F et al (2010) Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 9:305","journal-title":"Mol Cancer"},{"key":"12877_CR80","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/cancers14030474","volume":"14","author":"LJ Brown","year":"2022","unstructured":"Brown LJ, Achinger-Kawecka J, Portman N, Clark S, Stirzaker C, Lim E (2022) Epigenetic therapies and biomarkers in breast cancer. Cancers (Basel) 14:474","journal-title":"Cancers (Basel)"},{"key":"12877_CR81","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026948","volume":"7","author":"T Sato","year":"2017","unstructured":"Sato T, Issa J-PJ, Kropf P (2017) DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med 7:a026948","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12877-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:37Z","timestamp":1791673537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12877-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12877"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12877-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1705"}}